The Role of Diagnostics
Fast, accurate diagnostics are a key component of addressing sepsis and AMR together. “In the future, new technologies enabling real-time, near-patient diagnosis of sepsis and identification of antimicrobial susceptibilities of the associated infection will be crucial to reducing uncertainty and the need for empirical prescribing decisions prone to bias,” according to the article.
Prescribers and antimicrobial stewardship programs can already benefit from fast, comprehensive identification of bloodstream pathogens and associated antimicrobial resistance markers. The BioFire® Blood Culture Identification 2 (BCID2) Panel offers the ability to detect 33 pathogens (including gram-positive bacteria, gram-negative bacteria, and yeast) and 10 antimicrobial resistance markers—all with one test and results in about an hour after positive blood culture.
In fact, pairing the BioFire® FilmArray® Blood Culture Identification (BCID) Panel with an antimicrobial stewardship program has been shown to provide the greatest benefit in terms of antimicrobial de-escalation.4
When it comes to sepsis, it’s impossible to know what’s causing the underlying infection without diagnostic testing. Traditional testing can be slow and insensitive, and sepsis patients typically receive empiric broad-spectrum antibiotics while awaiting results. Syndromic testing from BioFire uses multiplex PCR technology to test for a broad menu of possible pathogens with one quick test, giving prescribers the information they need to make timely and targeted treatment decisions.